FinBERT, a financial-language model, scores this headline as positive (90% confidence). That is the news tone only — not the full stock rating.
Stocks › CORT
Corcept Therapeutics Inc (CORT) stock analysis
WEAK BUY 23% confidence · analysed Nov 4, 2026
On Nov 4, 2026, our model rated Corcept Therapeutics Inc (CORT) WEAK BUY with 23% confidence at a price of $81.93. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$81.93
Technical picture
The 14-day RSI is 18, below 30, which is oversold territory: sellers have pushed hard recently. Oversold stocks often bounce, but they can stay weak for a while.
MACD is below its signal line, so short-term momentum is pointing down.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is 1.5x its 20-day average, so the latest move has real participation behind it.
Fundamentals
The PEG ratio is 0.81, which looks cheap relative to its expected growth.
The company reports a profit margin of 6.6% and revenue growth of +31.7%.
In its latest quarter it earned $1.01 per share, which beat the $0.84 analysts expected, with revenue +31.7% year over year.
Wall Street's average rating is 2.0 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $141.00.
Trade plan from the model
The model's long / bullish plan uses an entry near $81.93, a target of $91.90 (+12.2%) and a stop-loss at $70.55 (-13.9%).
That is a reward-to-risk ratio of about 0.9 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 14, 2026 whatever the price does.
Entry$81.93
Target$91.90
Stop-loss$70.55
Reassess byNov 14, 2026
The model's one-paragraph read
Leans BUY — composite score +0.23 (WEAK BUY). Technicals: RSI 17.81, MACD bearish, price below SMA50. Fundamentals: PEG 0.81, margin 6.6%, revenue growth 31.7%. Financial results: YoY revenue +31.7%, last EPS surprise +20.2%. FinGPT news read: positive. Suggested levels: entry $81.93, target $91.9, stop-loss $70.55, exit by 2026-11-14 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for CORT
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 4, 2026 | WEAK BUY | 23% | $81.93 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on CORT
Nov 4, 2026 · Corcept Therapeutics Incorporated Reports Third Quarter 2026 Revenue of $340.5 million
- Nov 3, 2026: Corcept Therapeutics Incorporated Reports Third Quarter 2026 Revenue of $340.5 million (Nasdaq)
- Nov 3, 2026: Corcept's Breakout Quarter Collides With A Static Guide And A Stock Near Its Lows (Earnings Whispers)
- Nov 3, 2026: Corcept Therapeutics falls on guidance despite earnings beat (Investing.com)
- Nov 3, 2026: Corcept: Q3 Earnings Snapshot (Associated Press)
Frequently asked questions
Is CORT a buy right now?
As of Nov 4, 2026, our automated model rates Corcept Therapeutics Inc (CORT) WEAK BUY with 23% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for CORT?
The model's most recent plan targets $91.90 with a stop-loss at $70.55, from an entry near $81.93.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.